Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Stromedix: Untangling fibrosis

The biology of fibrosis and fibroblasts are well understood, and there are multiple pathways and targets known to regulate fibroblast activity. Yet there are no marketed drugs for fibrosis and relatively few in development, despite the importance of fibrosis in diseases of the liver, kidney, lung and heart, and morbidity and mortality equivalent to cancer. Stromedix Inc. hopes to change that equation.

Fibrosis is a tissue-level phenomenon resulting from the excessive activity of a form

Read the full 747 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE